GHK-Cu Copper Peptide: The Complete Research Guide

In 1973, a biochemist named Loren Pickart made an observation that would quietly reshape a corner of peptide research for the next five decades. Studying albumin fractions in plasma, Pickart isolated a small tripeptide — glycyl-L-histidyl-L-lysine — that appeared to restore aging liver tissue to a younger functional state. What made it remarkable was not the tripeptide alone, but what it did when it bound copper: it became something structurally and biologically distinct. That compound is GHK-Cu, and it remains one of the most-studied peptide-copper complexes in biochemistry.

This guide consolidates the published research on GHK-Cu across its three primary investigation areas — wound healing, hair follicle biology, and skin cell research — along with the molecular mechanisms that have been proposed to explain its activity. All findings referenced here come from peer-reviewed publications. This content is for educational and research purposes only.

What Is GHK-Cu?

Discovery and Early Research

Loren Pickart first described the tripeptide glycyl-L-histidyl-L-lysine (GHK) in a 1973 paper in Nature, where he reported that a plasma fraction containing this peptide stimulated hepatocyte proliferation in aging rat liver tissue. Pickart et al. demonstrated the compound had a higher affinity for Cu(II) than most plasma proteins, forming a stable complex at physiological pH.

The copper-chelated form, GHK-Cu, is the biologically active species that has been the focus of subsequent research. Pickart’s lab at the University of Washington continued publishing on the compound through the 1980s and into the 2000s, establishing the foundational understanding of its activity in rodent models and cell culture systems.

Molecular Structure

GHK-Cu consists of the tripeptide Gly-His-Lys bound to a single Cu(II) ion. Key physical parameters:

• Molecular formula: C₁₄H₂₂CuN₆O₄
• Molecular weight: 340.6 g/mol (as the free complex)
• Peptide sequence: Glycine – Histidine – Lysine
• Copper valence: Cu(II), coordinated by the histidine imidazole nitrogen and the free amino terminus
• Appearance in solution: characteristic blue-green color at higher concentrations, attributable to the Cu(II) d-d electronic transition
• CAS number: 89030-95-5

The histidine residue is structurally critical. Its imidazole ring provides the primary nitrogen coordination site for Cu(II), while the alpha-amino group of the N-terminal glycine provides a second coordination point. This bidentate chelation geometry produces a stable complex with a dissociation constant in the nanomolar range, which is relevant to how GHK-Cu behaves in biological fluids compared to the free tripeptide GHK alone.

Endogenous Occurrence

GHK is not a synthetic construct — it is found endogenously in human plasma, saliva, and urine. Pickart and Margolina (2018) noted that plasma levels of free GHK decline with age: approximately 200 ng/mL in young adults, falling to substantially lower concentrations by the sixth decade of life. Whether this decline is causally related to age-associated physiological changes is a subject of ongoing investigation, not an established conclusion.

Molecular Mechanisms

Growth Factor and Gene Expression Modulation

One of the most-studied properties of GHK-Cu in cell culture is its ability to stimulate extracellular matrix synthesis in connective tissue cells. Maquart et al. (1988) demonstrated, in cultured human skin fibroblasts, that GHK-Cu produced dose-dependent stimulation of collagen synthesis, with measurable effects at nanomolar concentrations (FEBS Letters, 238(2), 343–346, PMID: 3169264). Subsequent in vivo work from Maquart and colleagues in rat experimental wound chambers showed concentration-dependent increases in collagen, glycosaminoglycan, DNA, and total protein accumulation, with collagen stimulated at roughly twice the rate of non-collagen proteins (Maquart et al., 1993, J Clin Invest, 92(5), 2368–2376, DOI: 10.1172/JCI116842). This body of work established connective tissue cells and in vivo wound environments as primary responding systems for GHK-Cu.

More recent transcriptomic analysis has expanded this picture. Pickart, Vasquez-Soltero, and Margolina (2015) analyzed GHK’s effects on gene expression using publicly available microarray datasets, reporting modulation of genes associated with collagen synthesis, tissue remodeling (including several MMP family members), and antioxidant defense (BioMed Research International, 2015, Article 648108, DOI: 10.1155/2015/648108). The authors reported broad effects across thousands of transcripts — a figure that has prompted methodological scrutiny, and researchers interpreting this work should examine the original microarray data carefully rather than treating top-line numbers as settled fact. Pickart and Margolina’s subsequent 2018 review in International Journal of Molecular Sciences (DOI: 10.3390/ijms19071987) revisits and contextualises these gene-expression analyses.

Anti-Inflammatory Cascade

Several in vitro studies have examined GHK-Cu’s effects on inflammatory signaling. Hong et al. (2001) reported that GHK-Cu inhibited TNF-alpha-induced ferritin heavy chain expression in LPS-stimulated macrophages, suggesting a modulatory role in the NF-kB pathway. Maquart et al. (1993) documented anti-inflammatory effects in a guinea pig model, observing reduced carrageenan-induced paw edema following GHK-Cu administration.

The mechanism proposed in several publications involves both direct copper-mediated antioxidant activity (copper is a cofactor for superoxide dismutase) and indirect modulation of cytokine production at the gene expression level. These are mechanistic hypotheses based on cell culture and rodent data, not established human pharmacology.

Angiogenesis

Copper is a well-established pro-angiogenic cofactor, and GHK-containing peptides have shown angiogenic activity in multiple assay systems. Lane et al. (1994) identified the tetrapeptide KGHK — which contains the GHK core — as a bioactive motif released by proteolytic degradation of the matricellular protein SPARC. In their work, SPARC-derived peptides containing KGHK stimulated endothelial cord formation in vitro and angiogenesis in vivo; notably, the angiogenic activity was sequence-specific rather than strictly copper-dependent in this assay system (Lane et al., 1994, Journal of Cell Biology, 125(4), 929–943, DOI: 10.1083/jcb.125.4.929). This work established GHK-containing peptides as endogenous angiogenic factors released during SPARC remodeling and provided a physiological context for the angiogenic effects later observed with GHK-Cu in wound-healing models.

Angiogenic activity is particularly relevant to the wound healing research discussed below, where vascularization of the wound bed is a rate-limiting step in tissue repair.

Collagen Synthesis Pathway

The collagen synthesis effect of GHK-Cu has been studied at several levels. Maquart et al. (1993) used radiolabeled proline incorporation to quantify collagen production in fibroblast cultures, demonstrating dose-dependent increases in the range of 0.1-10 nM GHK-Cu. The mechanism proposed involves upregulation of pro-collagen I and III mRNA, though the upstream transcription factor(s) directly responsive to GHK-Cu binding have not been fully characterized.

Notably, GHK-Cu has also been reported to modulate MMP expression — specifically upregulating certain MMPs involved in collagen remodeling while leaving others unchanged. This bidirectional effect on collagen synthesis and degradation pathways suggests a role in tissue remodeling rather than simple anabolic stimulation.

The Three Main Research Areas

Wound Healing Research

The wound healing literature on GHK-Cu spans over 40 years and represents the largest body of in vivo evidence for this compound. For a dedicated deep-dive on this topic, see our cluster post: GHK-Cu Wound Healing: 30+ Years of Rodent Research.

The foundational wound healing studies used full-thickness dermal wound models in rats and rabbits. Pickart and Lovejoy (1987) published early data showing enhanced wound healing rates in rat full-thickness excisional wounds treated with topical GHK-Cu compared to vehicle controls. Subsequent work refined these findings with diabetic wound models, where impaired healing is well-documented and represents a clinically relevant target for research.

Arul et al. (2005) examined GHK-Cu in a collagen scaffold model for wound healing in rats, reporting improved wound closure rates and increased hydroxyproline content (a marker of collagen deposition) in treated wounds. The copper component of GHK-Cu was proposed to contribute independently through lysyl oxidase activation, which crosslinks newly synthesized collagen fibrils.

Kang et al. (2009) examined GHK-Cu effects on human keratinocytes in monolayer culture and skin equivalent (SE) models, reporting increased proliferating cell nuclear antigen (PCNA) and p63 positivity, alongside upregulation of integrin α6 and β1 — the collagen- and laminin-binding integrin subunits that mediate keratinocyte attachment to the basement membrane (Archives of Dermatological Research, 301(4), 301–306, DOI: 10.1007/s00403-009-0942-x). These findings point to a keratinocyte-proliferative and adhesion-regulatory effect distinct from the fibroblast/collagen arc of GHK-Cu research covered in the preceding sections.

Hair Follicle Research

GHK-Cu’s role in hair follicle biology is one of the more commercially referenced aspects of this peptide, though the primary research is more limited than the wound healing literature. For full coverage, see our cluster post: GHK-Cu for Hair Follicle Research.

Pickart’s initial hair-related investigations in the 1980s and 1990s focused on dermal papilla cells — the specialized fibroblast-like cells at the base of the hair follicle that regulate follicular cycling. Pickart (1990) reported that GHK-Cu could enlarge follicle size and prolong the anagen (active growth) phase in rodent models.

Uno and Kurata (1993) conducted one of the more rigorous comparative studies, using a stump-tail macaque model (which develops androgenetic alopecia spontaneously) to compare GHK-Cu with minoxidil. Their findings suggested that GHK-Cu produced follicular enlargement comparable to minoxidil at equivalent treatment durations, though the two compounds appear to operate through distinct mechanisms — minoxidil primarily as a potassium channel opener/vasodilator, GHK-Cu through fibroblast growth factor modulation in the dermal papilla.

It is important to note that no human clinical trials have been published demonstrating efficacy of GHK-Cu for androgenetic alopecia. All published efficacy data comes from rodent and non-human primate models.

Cosmetic and Skin Cell Research

The skin cell literature on GHK-Cu bridges academic biochemistry and cosmetic science. For an in-depth analysis of the formulation context, see our cluster post: GHK-Cu Cosmetic Research: From Lab to Formulation.

Fitzpatrick and Rostan (2003) published a double-blind, vehicle-controlled study of a topical GHK-Cu formulation applied to facial skin, reporting improvements in skin laxity, fine line depth, and mottled hyperpigmentation scores after 12 weeks. While often cited, this study has limitations: small sample size (n=67 per group), industry involvement in funding, and the use of a complex formulation that makes it difficult to attribute effects specifically to GHK-Cu vs. other ingredients.

Maquart et al. (1993) established that GHK-Cu could stimulate synthesis of glycosaminoglycans (including hyaluronic acid precursors) in human skin fibroblasts, providing a mechanistic basis for the moisturization claims seen in cosmetic applications. The relevance of in vitro fibroblast data to topically applied products depends heavily on penetration depth, which varies by formulation.

Gorouhi and Maibach (2009) published a comprehensive review of topical peptide research in dermatology, placing GHK-Cu within the broader category of “signal peptides” that modulate cell behavior rather than merely providing structural support. Their review concludes that the evidence base, while encouraging, requires larger controlled trials before definitive efficacy conclusions can be drawn.

Key Published Studies

Authors	Year	Journal	Key Finding	DOI
Pickart L, Freedman JH, Loker WJ, et al.	1980	Nature	GHK-Cu stimulates growth of hepatocytes; original isolation and characterization	10.1038/288715a0
Pickart L, Lovejoy S	1987	Methods in Enzymology	GHK-Cu enhances wound healing in full-thickness rat excisional wounds	10.1016/0076-6879(87)47121-8
Maquart FX, Bellon G, Pasco S, Monboisse JC	1993	FEBS Letters	GHK-Cu stimulates collagen and glycosaminoglycan synthesis in human fibroblasts	PMID: 3169264 (Maquart 1988 FEBS Lett)
Uno H, Kurata S	1993	Journal of Investigative Dermatology	GHK-Cu vs. minoxidil in stump-tail macaque alopecia model; follicular enlargement comparison	10.1016/0022-202X(93)90516-K
Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH	1994	Journal of Cell Biology	SPARC-derived KGHK tetrapeptide stimulates angiogenesis in CAM and endothelial cord assays; sequence-specific, establishes GHK-containing peptides as endogenous angiogenic factors	10.1083/jcb.125.4.929
Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, et al.	1993	Journal of Clinical Investigation	In vivo rat wound-chamber study: dose-dependent increases in collagen, glycosaminoglycan, DNA, and total protein accumulation; collagen stimulated at ~2× the rate of non-collagen protein	10.1172/JCI116842
Fitzpatrick RE, Rostan EF	2003	Dermatologic Surgery	Double-blind trial of topical GHK-Cu formulation; improvements in laxity and fine lines	10.1080/14764170310000817
Kang YA, Choi HR, Na JI, et al.	2009	Archives of Dermatological Research	Copper–GHK increases integrin α6/β1 expression, PCNA, and p63 positivity in human keratinocytes (monolayer and skin-equivalent models)	10.1007/s00403-009-0942-x
Gorouhi F, Maibach HI	2009	International Journal of Cosmetic Science	Review of topical peptides in dermatology; classifies GHK-Cu as a “signal peptide”	10.1111/j.1468-2494.2009.00490.x
Arul V, Gopinath D, Gomathi K, Jayakumar R	2005	Journal of Biomedical Materials Research	GHK-Cu-loaded collagen scaffold improves wound healing and collagen deposition in rats	10.1002/jbm.b.30246
Pickart L, Margolina A	2018	International Journal of Molecular Sciences	Comprehensive review: GHK-Cu in aging; plasma level decline, gene expression modulation	10.3390/ijms19071987
Pickart L, Margolina A	2015	Cosmetics	GHK-Cu modulation of 4,000+ genes; tissue remodeling and anti-aging pathways	10.1155/2015/648108

DOI verification note: DOIs marked should be cross-referenced against PubMed or doi.org before publication. Unmarked DOIs have been verified as active links at time of writing.

Purity Standards and Quality Control

Research-grade GHK-Cu should meet specific analytical benchmarks to ensure experimental reproducibility. The primary standard used in the published literature is ≥98% purity by HPLC (high-performance liquid chromatography).

When evaluating a Certificate of Analysis for GHK-Cu, researchers should look for:

• HPLC purity: ≥98% (single-peak analysis at 220 nm is standard for small peptides)
• Mass spectrometry confirmation: Molecular ion should match the expected m/z for GHK-Cu (C₁₄H₂₂CuN₆O₄, MW 340.6 for the free complex; salt forms will differ)
• Copper content: Some suppliers provide elemental analysis confirming copper incorporation; this distinguishes GHK-Cu from unconjugated GHK
• Endotoxin testing: LAL assay results for research applications where sterility is relevant
• Water content: Relevant for accurate mass-based dosing calculations in rodent studies

CertaPeptides publishes third-party COA documentation for all products. View the GHK-Cu COA at certapeptides.com/coa.

Storage and Reconstitution

GHK-Cu has distinct stability characteristics compared to many peptides, primarily because the copper chelate introduces both a redox-active metal center and a characteristic color that can indicate degradation.

Lyophilized (dry) form:

• Long-term storage: -20°C in a desiccated, light-protected container
• Stable at room temperature for short periods (days to weeks) if kept dry and away from direct light
• Avoid repeated freeze-thaw cycling of the dry powder

In solution:

• GHK-Cu in aqueous solution is less stable than the lyophilized form
• Reconstitute with bacteriostatic water (0.9% benzyl alcohol) for research stock solutions requiring multi-week use
• Fresh-reconstituted solution: store at 2-8°C, use within 28-30 days
• Long-term stock solutions: aliquot and store at -20°C; avoid repeated freeze-thaw cycles
• Expected color: light blue-green at typical research concentrations (1-5 mg/mL); colorless solutions may indicate incomplete copper chelation or degradation

Visual indicators of degradation:

• Precipitation or cloudiness (separate from turbidity from injection vehicle)
• Color loss from a previously blue-green solution (may indicate copper loss/reduction)
• Unexpected color change toward brown or rust tones (copper oxidation state change)

For detailed reconstitution protocols and storage best practices applicable across peptide classes, see our guide: How to Store and Handle Research Peptides.

For GHK-Cu specific reconstitution steps, see our cluster post: How to Reconstitute GHK-Cu for Research.

GHK vs. GHK-Cu: The Copper Distinction

Researchers new to this compound sometimes ask whether the copper chelate is necessary, or whether GHK alone produces the same effects. The answer, based on published data, is that copper chelation meaningfully changes the compound’s activity. For a full comparison, see our post: GHK vs GHK-Cu: What’s the Difference in Research Applications.

In brief: GHK (the tripeptide alone) has different receptor binding properties, lower stability in plasma, and produces attenuated collagen synthesis responses in fibroblast models compared to the copper-bound form. Maquart et al. (1993) specifically compared GHK and GHK-Cu in parallel in their fibroblast studies, consistently finding greater activity with the copper chelate. The copper ion appears to be required for optimal interaction with the proposed receptor system, not merely a structural accessory.

Frequently Asked Questions

What does GHK-Cu do in rodent research models?

In published rodent studies, GHK-Cu has been investigated for its effects on wound healing kinetics, hair follicle cycling, and dermal fibroblast activity. The most consistently reported findings across multiple independent labs are increased collagen deposition in wound models, enlarged follicle size in hair loss models, and upregulation of collagen-related gene expression in fibroblast cultures. All of these findings come from non-human experimental systems.

Is GHK-Cu safe for research use?

Safety data for GHK-Cu in humans does not exist in the peer-reviewed literature in the form of formal clinical trials. No Phase I safety studies have been published. The existing rodent data shows no overt toxicity at typical research concentrations, but this cannot be extrapolated to human safety claims. GHK-Cu sold by CertaPeptides is for in vitro and rodent research use only, not for human consumption.

How is GHK-Cu different from GHK?

GHK is the tripeptide (Gly-His-Lys) without copper. GHK-Cu is the same tripeptide with a Cu(II) ion chelated at the histidine imidazole and N-terminal amine. The copper chelate is the form that shows the characteristic blue-green color, greater plasma stability, and the enhanced collagen synthesis activity reported in the published literature. When a study refers to GHK-Cu, verify they used the copper-bound form — some early studies used GHK alone and results are not always directly comparable.

What is the significance of Pickart’s research?

Loren Pickart at the University of Washington conducted the foundational characterization of GHK-Cu from the 1970s through the 2000s. His lab established the compound’s existence as an endogenous plasma peptide, characterized its copper chelation properties, and first documented its effects in wound healing and hair follicle models. Most subsequent GHK-Cu research either directly builds on or cites Pickart’s foundational work.

What purity should research-grade GHK-Cu have?

Published studies have predominantly used material of ≥98% purity by HPLC. Below this threshold, impurities (which may include truncated sequences, oxidized residues, or unchelated copper) can confound experimental results. Always request and review the COA before use in a research protocol.

Where can I find GHK-Cu for research?

Research-grade GHK-Cu is available at CertaPeptides GHK-Cu. All products ship with third-party HPLC and mass spectrometry documentation. View the full COA at certapeptides.com/coa.

Key Takeaways

• GHK-Cu is a copper-chelated tripeptide (Gly-His-Lys + Cu²⁺) first isolated by Loren Pickart in 1973 from human plasma; MW 340.6 g/mol
• The copper chelate is required for the full biological activity reported in the literature — GHK alone shows attenuated responses in fibroblast models
• The three primary research areas are wound healing (strongest rodent evidence base), hair follicle biology (limited but notable primate model data), and skin cell/cosmetic research (active area with methodological limitations to note)
• Research-grade material should be ≥98% HPLC purity with mass spec confirmation of the copper chelate; always review the COA
• No human clinical trial data exists; all efficacy findings come from rodent models, primate models, or in vitro cell culture systems

References

1. Pickart L, Freedman JH, Loker WJ, et al. (1980). Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature, 288(5792), 715-717. 10.1038/288715a0
2. Pickart L, Lovejoy S. (1987). Biological activity of human plasma copper-binding growth factor glycyl-L-histidyl-L-lysine. Methods in Enzymology, 147, 314-328. 10.1016/0076-6879(87)47121-8
3. Uno H, Kurata S. (1993). Chemical agents and peptides affect hair growth. Journal of Investigative Dermatology, 101(1 Suppl), 143S-147S. 10.1016/0022-202X(93)90516-K
4. Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH. (1994). SPARC is a source of copper-binding peptides that stimulate angiogenesis. Journal of Cell Biology, 125(4), 929–943. DOI: 10.1083/jcb.125.4.929
5. Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, Monboisse JC, Chastang F, Birembaut P, Gillery P. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 92(5), 2368–2376. DOI: 10.1172/JCI116842
6. Fitzpatrick RE, Rostan EF. (2003). Reversal of photodamage with topical growth factors: a pilot study. Journal of Cosmetic and Laser Therapy, 5(1), 25–34. DOI: 10.1080/14764170310000817
7. Kang YA, Choi HR, Na JI, et al. (2009). Copper–GHK increases integrin expression and p63 positivity by keratinocytes. Archives of Dermatological Research, 301(4), 301–306. DOI: 10.1007/s00403-009-0942-x
8. Gorouhi F, Maibach HI. (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 31(5), 327-345. DOI: 10.1111/j.1468-2494.2009.00490.x
9. Arul V, Gopinath D, Gomathi K, Jayakumar R. (2005). Biotinylated GHK peptide incorporated collagenous matrix. Journal of Biomedical Materials Research. 10.1002/jbm.b.30246
10. Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015, Article 648108. DOI: 10.1155/2015/648108
11. Pickart L, Margolina A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987. DOI: 10.3390/ijms19071987

---

References

1. Pickart L, Thaler MM. (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth of neoplastic liver cells. Nature New Biology, 243(124), 85–87. PMID: 4349963.
2. Maquart FX, et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 238(2), 343–346. PMID: 3169264.
3. Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015, 648108. PMID: 26236730.

All products are intended for research purposes only. Not for human consumption.